ESR1 and breast carcinoma: In the TBCRC 006 study, patients with ER‐positive, HER2‐positive stage II–III breast cancer who received neoadjuvant lapatinib and trastuzumab plus letrozole achieved a total pCR (tpCR) rate of 18% with minimal side effects.19